Maraviroc

Medical Advocates
Maraviroc (Selzentry)

Conference Citations

4th IAS Conference
14th CROI
8th Int Congress on Drug Therapy in HIV Infection
XVI International AIDS Conference
13th CROI
3rd IAS Conference

Maraviroc Main Page

Main New/Newsworthy

Home Page

Last Update: July 05, 2008

Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

14th Conference on Retroviruses and
Opportunistic Infections

Virological Correlates Associated with Treatment Failure at Week 48 in the Phase 3 Study of
Maraviroc in Treatment-naive Patients
J Heera, M Saag, P Ive, J Whitcomb
Abstract
POSTER
Comparison of Results from the SensiTrop vs Trofile Assays on 100 Samples from the Maraviroc
Expanded Access Program
R Tressler, H Valdez, E van der Ryst, et al
PDF Poster Abstract
POSTER
Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Treatment-experienced
Patients Infected with CCR5-Tropic HIV-1: 48-Week Combined Analysis of the MOTIVATE Studies
D Hardy, J Reynes, I Konourina, et al
PDF Poster Abstract
Maraviroc (MVC) Pharmacokinetics (PK) in Blood Plasma (BP), Genital Tract (GT) Fluid and
Tissue in Healthy Female Volunteers
J Dumond, K Patterson, A Pecha, et al
Abstract
POSTER
Changes in V3 Loop Sequence Associated with Failure of Maraviroc Treatment in Patients
Enrolled in the MOTIVATE 1 and 2 Trials
M Lewi, J Mori, P Simpson, et al
PDF Poster Abstract
POSTER
Fasted Lipid Changes after Administration of Maraviroc or Efavirenz in Combination with Zidovudine
and Lamivudine for 48 weeks to Treatment-naïve HIV-infected Patients
E DeJesus, S Walmsley, C Cohen, et al
PDF Poster Abstract

47th Interscience Conference on Antimicrobial Agents
and Chemotherapy

POWERPOINT PRESENTATION
Efficacy and Safety of Maraviroc in Antiretroviral-Experienced Patients Infected With
CCR5-Tropic HIV-1: 48-Week Results of MOTIVATE 1
J Lalezari, J Goodrich , E DeJesus, et al
Presentation

4th IAS Conference on HIV Pathogenesis, Treatment
and Prevention

NEWS RELEASE
Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show
Monogram Biosciences July 25, 2007
Efficacy and safety of once-daily (QD) compared with twice-daily (BID) maraviroc plus
optimized background therapy (OBT) in treatment-experienced patients infected with CCR5-
tropic-HIV-1: 24-week combined analysis of the MOTIVATE 1 and 2 studies
Gulick RM, van der Ryst E, Lampiris H, et al
Abstract
Efficacy of Maraviroc in combination with at least one other potent new antiretroviral drug: 24-week
combined analysis of the MOTIVATE 1 and 2 studies
van der Ryst E., Cooper D., Konourina I, et al
Abstract
A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist,
maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine
[3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: Week 48
results of the MERIT study
Saag M, Ive P, Heera J, et al
Abstract

14th Conference on Retroviruses and
Opportunistic Infections

Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic ART-experienced
Patients Infected with CCR5-tropic HIV-1: 24-Week Results of a Phase 2b/3 Study in the US and
Canada
J Lalezari, J Goodrich, E DeJesus, et al
Abstract
A Review of the Markers of Immune Function during the Maraviroc Phase I and IIa Studies
A Ayoub, E Van der Ryst, K Turner, M McHale
Abstract
Efficacy and Safety of Maraviroc plus Optimized Background Therapy in Viremic, ART-experienced
Patients Infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-Week Results
M Nelson, G Fätkenheuer, I Konourina, et al
Abstract

8th Int Congress on Drug Therapy in HIV Infection

Selective suppression of R5 HIV-1 by the novel CCR5 antagonist maraviroc (MVC) is associated
with maintenance of CD4 cell counts in antiretroviral-experienced patients (pts) infected with
dual/mixed-tropic (D/M) HIV-1
van der Ryst E., Mayer H., Goodrich J.M., et al
Abstract

XVI International AIDS Conference

The mechanism of HIV-1 escape from small molecule CCR5 antagonists
P. Pugach, S. Kuhmann, T. Ketas, J.P. Moore
Abstract

13th Conference on Retroviruses and
Opportunistic Infections

PDF POSTER
Maraviroc Is a Slowly Reversible Antagonist at the Human CCR5 in a CRE Luciferase Reporter
Gene Assay
S Pullen, H Sale, C Napier, et al
Poster
PDF POSTER
Resistance to the CCR5 Antagonist Maraviroc Is Characterised by Dose-Response Curves that
Display a Reduction in Maximal Inhibition
M Mosley, C Smith-Burchnell, J Mori, et al
Poster

3rd IAS Conference on HIV Pathogenesis, Treatment
and Prevention

Overview of phase 1 and 2a safety and efficacy data of maraviroc (UK-427,857)
McHale M., Abel S Russell D.
Abstract

Maraviroc Main Page

Main New/Newsworthy

Home Page

Maraviroc (Selzentry) Conference Citations